Americas

Abbott Laboratories Biotech Facility
Barceloneta, where the new Abbot Laboratories facility is based, is on the northern coast of the island of Puerto Rico.	Humira has now been approved for the treatment of psoriasis in Europe.	Humira is a CAT-derived human anti-tumour necrosis factor alpha which mediates inflammation.
Puerto Rico is a Caribbean island which is effectively a protectorate of the US. The island offers significant tax advantages and incentives to companies locating facilities there.

ABC Laboratories, Pharmaceutical Facility,
The new ABC facility is situated just southwest of Columbia.	The lab space has been outfitted and as of June 2008 is being occupied.	There is a central services arrangement at the new ABC facility.
The facility has 20ft-high ceilings and as much natural light as possible is being channelled into the building.	The new building has 30,000ft² of office and 60,000ft² of laboratory space.

Accucaps Industries, Manufacturing Capacity, Ontario
The Strathroy facility in Ontario began a project in April 2008 to double production capacity.	Accucaps is one of the largest soft gel cap manufacturers in North America.	The Accucaps facility in Strathroy has been converted to focus on health and nutritional products.
The company's strategy is based on stronger legislation for food and health products from the Canadian Government.

Achillion Pharmaceuticals Biotech Facility,
New Haven County is seeing an increasing number of biotechnology investments which should play a vital role in revitalising the local economy.	The opening ceremony of the New Haven Biotech facility was held in December 2000.	Zinc finger proteins are essential to the Achillion Pharmaceuticals growth strategy.
Zinc finger proteins allow proteins to recognize nucleic acids (DNA or RNA) and thus modulate genes that the nucleic acids encode. The diagram shows carbon tube tracings, which illustrate the distinct 3-dimension structures of various representative human zinc finger “CCCC”, and “CCHH”motifs, versus the retroviral 'CCHC' motif.

Amgen Helix Project
The Helix project is a $750 million research and development facility in Seattle.	The first phase of construction is due to be completed in 2003.	The Helix construction includes a bridge over the railway, which will be open to the public.

Amgen Pharmaceutical Manufacturing Facility,
Immunex decided to purchase an existing manufacturing facility in West Greenwich, and retrofit it to produce the Enbrel drug.	Work on the BioNext project in West Greenwich began in November 2001.	Part of the utilities infrastructure at the new BioNext mammalian protein manufacturing facility.
Immunex has also recently invested in a pharmaceutical facility in Bothell in Washington.	Part of an interim Enbrel manufacturing site at West Greenwich owned by Wyeth-Ayerst Pharmaceuticals and using Immunex's process technology.	The plant is now fully operational.
The water treatment plant will use 800,000 gallons per day.

Amgen Process Development Facility,
The Immunex facility at Bothell needed specially constructed water pipe systems for the supply of its exceptionally pure water. These had to be made with specialised machines.	The process development facility at Bothell was the third major facility to be built there.	The process development facility at Bothell was in use by the end of 2001.
The Bothell facility covers 50,000ft².	The Bothell process development facility saw production gradually geared up during the course of 2001 to full capacity by the opening of 2002.	As well as the Bothell facility, Immunex is also investing in facilities in Seattle (the Helix project).

Amylin Pharmaceuticals
Insulin secretion mechanism from the pancreas.	Amylin's exanetide suppresses glucagon secretion in the pancreas.	Byetta (exanetide) is injected twice a day. A long-acting version is also in development by Amylin.
Amylin is a peptide secreted from the pancreas beta cells which mediate in insulin secretion.	The biopharma manufacturing facility is set to be complete in late 2008.	Amylin has received over $117m in benefits and assistance for locating its manufacturing facility in Ohio.

AstraZeneca Bulk Pharmaceutical
AstraZeneca's facility in Guayama, Puerto Rico.	PRIDCO hopes that Zeneca's investments will enhance the island’s reputation as a manufacturing centre.	According to the company's own figures, its soluble, oral version of Zomig was widely welcomed by the sample group. If this is the case, it should boost demand.

Baxter BioPharma Solutions Parenteral
The Bloomington plant manufactures pre-filled syringes, vials and cartridges for the packaging of vaccines and drugs.	The pre-filled syringe production facility consists of 24 modules that include formulation, preparation and supporting utility rooms.	Research and development in formulation.
Production equipment area.	Skid/module being fabricated.	High-speed syringe filling line.
Module being put in place on prepared foundations at the Phase IV extension.	Completed prep room at the new extension.	Separate services area.

Bayer Corporation Biotechnology Plant
Bayer Manufacturing's multipurpose biotechnology plant in Berkeley, California, USA.	US spending on health is predicted to rise steadily in line with rising GDP.	The plant is a cGMP-FDA validated facility, and is the first in North America to meet one of the most rigorous international environmental standards in the world, the ISO 14001 standard.
Kogenate FS produced by Bayer at Berkley is one of the best selling factor VIII products for the treatment of haemophilia.

Berlex Biopharmaceutical Plant, Snohomish County, Washington State
The Northpointe Corporate Center has a range of occupants from pharmaceutical companies to semiconductor manufacturers.	The administration block in a state of construction.	Construction at the Northpointe Corporate Center well underway by Skanska USA.
Berlex produces a range of other drugs for the North American market including the contraceptive pill.	The inflammatory process brought on by Crohn’s disease, which can be relieved by the use of Leukine. The drug is still awaiting approval for this use.

Biolex Therapeutics Facility Expansion, Pittsboro, North Carolina
Lemna being grown on a small scale for development.	The new Biolex Hepatitis treatment Locteron in development.	The plant growth room in the new facility.
The Biolex facility in Pittsboro.	The Lemna (Duckweed) plant in its natural environment.

Biopol Allergy Immunotherapy Manufacturing Facility, Idaho
The new Biopol plant from a front elevation. The facility is expected to create approximately 50 jobs when completed in 2009.	A plan view of the new Biopol plant. It will be the largest production site of raw materials for the company's products.	Grass pollen is a big problem for allergy sufferers.
Pollen particles make excellent allergens, causing a lot of suffering for many people during the summer months.	Gravax is a new sublingual treatment for hay fever sufferers that is conveniently administered as a fast-dissolving tablet

Biosite HQ and Manufacturing Campus, Mera Misa, California
Cardiac profiler testing apparatus used to examine blood from cardiac patients and aid diagnosis.	One of the R&D laboratories.	Part of the new headquarters and campus buildings.
The triage parasite panel is an enzyme immunoassay used for the detection of antigens and is used as an aid in the diagnosis of intestinal parasitic disease.	Biosite has broadened its BNP product line to include the triage BNP test for Beckman Coulter immunoassay systems.

Bristol Myers Squibb
The city of New Brunswick in the US is known as the healthcare capital because of the number of pharmaceutical companies based there, including BMS.	Taxol is just one drug which has been a great success story for BMS.	Development of specific drugs takes time and money. The new centre at New Brunswich should help to make the process more rapid and more efficient.
The ODS areas at the BMS plant all have high containment and isolator technology.	BMS recently won the Facility of the Year 2008 award for equipment innovation at the New Brunswick plant.

Bristol Myers Squibb Manufacturing Plant,
The new Bristol Myers Squibb plant is situated in Devens, 35 miles northwest of Boston, Massachusetts,US.	The facility will have six 20,000l reactors for the manufacture of multiple biotech products.	The state of Massachusetts passed new legislation to offer greater incentives for the BMS plant to be located in Devens, allowing the company to claim a refund for 5% of its investment.
The new Bristol Myers Squibb facility has a $600,000 wastewater pre-treatment plant, designed to handle a flow capacity of 530,000gal per day.	The BMS facility is being built on a business park developed on the site of Fort Devens, which closed in 1996. The site was purchased by MassDevelopment.

Bristol-Myers Squibb,
Orencia is a new treatment for rheumatoid arthritis and will now be produced at the Manatí plant.	BMS has invested $220m in the Manatí plant and there is further expansion on the cards.	Orencia is produced in a solid dosage form.
Manati is in the north of Puerto Rico and is due to become a major centre for biologics production for BMS.	The damage caused by the inflammatory process set up by rheumatoid arthritis; Orencia controls inflammatory responses.

Cambridge Major Laboratories Active Pharmaceutical
Construction of the first floor of the new API production facility.	[top] back view of the facility [middle] area where pilot plants will be installed [bottom] area where 500 gallon reaction vessel will be installed.	Images showing building work with emphasis on roof construction.
[top] shipping and receiving area [bottom] billboard of site showing illustration of completed facility.	A view showing reactors in the Oread pilot plant purchased by Cambridge Major in 2002.

Cedarburg Pharmaceuticals Intermediate and API
Cedarburg Pharmaceuticals, LLC are making a number of investments in the facility.	Emerson Process Management was given the lead contract for automation at the Grafton pharmaceutical plant.	Cedarburg Pharmaceuticals' facility in Grafton, Winsconsin, USA.
A graph showing health expenditure as a percentage of GDP.

Chao Center for Industrial Pharmacy and Contract
The Allen Chao Centre for Industrial Pharmacy and Contract Manufacturing was coordinated and designed by Purdue Architects and Lockwood Greene / CH2MHill.	A map of the Purdue Research Park - the Chao Centre facility is one of only five university-affiliated pharmaceutical manufacturing centres in the United States.	The changing room for staff to use prior to entering high-grade cleanroom - the cGMP areas are required to be completely secure, operate under differential air pressure and be manned by highly trained individuals.
The first drugs to come off the production line are expected to be antibiotics that are effective for treating Multiple-Drug Resistant Tuberculosis (MDR-TB).	The cGMP compliant facility will assist with the development and production of legacy drugs, which are drugs for diseases and conditions that affect the underprivileged, especially in third-world countries.	Five multi-use rooms are part of the 10,000ft² of good manufacturing process space at the Chao Centre for Industrial Pharmacy and Contract Manufacturing.
A microscopic view of TB bacillus in sputum (stained red).

ChemSyn (Aptuit) Pharmaceutical Manufacturing Plant,
The exterior of the expanded Harrisonville pharmaceutical manufacturing facility.	The main reactor room at Harrisonville.	The isolation suite at the Harrisonville plant.
The drying/packaging suites.	Isolation hoods at the facility.	The Schott Scrubber system.

Cook Pharmica Biotechnology Plant
The old Thomson plant from the air.	The new Cook Pharmica campus.	Chromatography equipment installed at the biotechnology plant.
QA labs at the Cook Pharmica Biotechnology plant.	Buffer and media preparation and storage.

Cortex Biotech Facility, Missouri
The new CORTEX ONE building as an artist's rendering.	A map to show the extent of CORTEX property in St. Louis for development.	The CORTEX ONE building completed.
CORTEX ONE during construction.	The campus will provide space for biotech companies to develop.

Dendreon Biopharmaceutical Manufacturing Plant, Seattle
Prostate cancer is the third most prevalent cancer worldwide.	A micrograph of prostate cancer.	The Dendreon plant has scaled back its cleanrooms from 48 to 12.
The New Jersey site is on the other side of the US from Dendreon's Headquarters in Seattle.	Provenge is expected to be approved by the FDA when additional evidence from clinical trials is produced.

DSM Biologics Biopharmaceutical Manufacturing
DSM Biologics laboratory technician monitoring media preparation.	PER.C6 cell line for production of recombinant proteins.	A view of the top of a bioreactor skid.
DSM technical staff working in clean room facilities.	A tumbler for use in the production process.	The vitamin premix plant in Mexico is state-of-the-art.
DSM is currently considering new investment, but this may be hampered by increased prices of raw materials used for vitamins.	Vitamin products being packaged; the most sophisticated new technologies were used for production.	The plant also produces vitamins in traditional forms for the Latin American market.

DSM Premix Vitamin Plant,
Location of Roche´s El Salto vitamin premix plant.

Eastman Chemical Company
Eastman Chemical Company broke ground on its good manufacturing practice (cGMP) facility, the first of two US cGMP manufacturing facilities to be built at Eastman's Arkansas site, in 1999.	Eastman Chemical Company's new facility in Batesville, Arkansas, USA.	Graph showing relationship between spending on health and GDP.

Eli Lilly Biotech Pilot Plant, Indianapolis
The new K 360-362 building complex.	The support laboratories will form the nerve centre of Eli Lilly R&D.	Biotech equipment at the plant is state-of-the-art.
Even though the plant is pilot scale it is fully capable of producing commercial quantities of drug substance.	All equipment is fully automated and regulated.

Eli Lilly Humalog Manufacturing Facility, Carolina
Eli Lilly began production of the insulin product Humalog at its new bulk manufacturing facility in Carolina, Puerto Rico, in mid-2005.	Pro-insulin and human insulin, showing where the trypsin cleavage occurs.	Scanning electron micrograph of E. coli as used for recombinant DNA techniques.
Humalog pen used for dispensing the insulin by a non-injection technique.	Insulin crystals from the purification process.

Fiocruz
The new Fiocruz facility is part of an existing vaccine technological complex comprised of three main buildings: the bacterial vaccines production unit, the centre of final processing and the viral vaccine production unit (which was the last unit to be completed).	Water piping and compressed air services in the vaccine manufacturing centre.	Fiocruz Instituto de Tecnologia em Imunubiologicos' facility in Manguinhos near Rio de Janeiro, Brazil.

Genentech Cell Culture Plant No 2 Expansion
Herceptin will be one of the major products from Genentech's new CCP2 facility.	Vacaville is in northern California, about 58 miles from the Genentech HQ in San Francisco.	Xolair is Genentech's new product for the treatment of allergic asthma.
Sjorgens syndrome is an autoimmune condition which can be treated successfully with Rituxan, another drug to be made at the new CCP2 facility in Vacaville.	Genentech now has over 50 peptide and antibody products in its commercial pipeline.

Genentech Inc
Genentech is building the new fill and finish facility on a 75-acre site near Hillsboro in Oregon.	The new Genentech facility is expected to begin production by 2010 and will focus on products to treat cancer, arthritis and asthma, as well as those to promote tissue growth and repair.
The drug Herceptin is one of Genentech's success stories; the company is regarded as a pioneer in the biotech industry.	The State of Oregon has provided financial incentives for Genentech to relocate its fill and finish facility there.

Genentech Manufacturing Facility (NIMO)
The New Idec Manufacturing Operation (NIMO) at Oceanside, San Diego, was completed by Biogen Idec in 2005 and sold to Genentech later that year.	Fermentation vessels in the manufacturing hall.	Following FDA approval, Genentech will manufacture its colon cancer drug, Avastin, at Oceanside.
Avastin (white monoclonal antibody) acting upon cancerous cells.	The NIMO site, showing the manufacturing building partially completed in the foreground.	The plant is now ready to produce the new anticancer treatment Avastin.

GlaxoSmithKline Manufacturing and Packaging
Map showing the location of Zebulon.

ImClone Systems Biopharmaceutical Plant,